Advertisement

Clinical Rheumatology

, Volume 30, Issue 7, pp 993–996 | Cite as

Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease

  • Victoria Navarro-Compán
  • Virginia Moreira
  • Rafael Ariza-ArizaEmail author
  • Blanca Hernández-Cruz
  • Carmen Vargas-Lebrón
  • Federico Navarro-Sarabia
Brief Report

Abstract

This study aims to explore the effectiveness of low dose of etanercept (ETN) in patients with ankylosing spondylitis (AS) who achieve a good control of their disease in daily clinical practice. This is a case series of AS patients treated with ETN. According to the judgment of the treating rheumatologist and patient's preferences, a dose reduction was done in those patients who achieved a good control of their disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) <4 and C-reactive protein normal values. Fifty-one AS patients treated with ETN were identified and 16 of them (32%) were on dose reduction regimen. Several regimens of dose reduction were used. These patterns were fixed and they did not change along the time. Mean time receiving ETN before adjusting the dose was 17 ± 12 months. Mean follow-up after dose change was 21 ± 21 months. At this point, all the patients in whom dose reduction was done remained in the low-dose regimen. Median BASDAI (range) at starting the low-dose regimen and 6 months later were 1.6 (0.9–2.4) and 1.4 (0.3–3.2), respectively. Median CRP values (range) at starting the low dose regimen and 6 months later were 1 mg/l (0.1–2.8), and 1.3 mg/l (0.3–4.1), respectively. Other disease-related variables also remained unchanged. Patients with follow up at 12 and 24 months and longer remained in clinical remission with BASDAI values <2 and normal CRP values. Our data suggest that AS patients in clinical remission can use low doses of ETN without increasing disease activity. So, it can be a promising strategy but additional studies are needed to prove it.

Keywords

Ankylosing Spondylitis Anti-TNF dose reduction Anti-TNF therapy Etanercept 

Notes

Disclosures

None.

References

  1. 1.
    Ward MM (1998) Quality of life in patients with ankylosing spondylitis. Rheum Dis Clin North Am 24:815–827PubMedCrossRefGoogle Scholar
  2. 2.
    Braun J, Bollow M, Reminger G, Eggens U, Rudwaleit M, Distler A, Sieper J (1998) Prevalence of spondyloarthropaties in HLA-B27 positive and negative blood donors. Arthritis Rheum 41:58–67PubMedCrossRefGoogle Scholar
  3. 3.
    Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52:582–591PubMedCrossRefGoogle Scholar
  4. 4.
    Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64:1557–1562PubMedCrossRefGoogle Scholar
  5. 5.
    Van der Heijde D, Kinitz A, Schiff M, Sieper J, Dijkmans B, Braun J, Dougados M, Reveille J, Wong R, Kupper H, Davis JC (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Arthritis Rheum 54:2136–2146PubMedCrossRefGoogle Scholar
  6. 6.
    Van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58:1324–1331PubMedCrossRefGoogle Scholar
  7. 7.
    Marzo-Ortega H, Emery P, McGonagle D (2002) The concept of disease modification in spondyloarthropathy. J Rheumatol 29:1583–1585PubMedGoogle Scholar
  8. 8.
    Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRefGoogle Scholar
  9. 9.
    Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F (2004) La versión española del BASDAI es fiable y se correlaciona con la actividad de la enfermedad. Rev Esp Reumatol 31:372–378Google Scholar
  10. 10.
    Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49:483–487PubMedCrossRefGoogle Scholar
  11. 11.
    Baraliakos X, Listing J, Brandt J, Rudwaleit M, Sieper J, Braun J (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7:R439–R444PubMedCrossRefGoogle Scholar
  12. 12.
    Amtembrink A, Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong R, Kupper H, Braun, Sieper J (2008) Adalimumab successfully re-treats and mantains long-term efficacy in axial spondyloarthritis patients without radiographic sacroilitis who relapse following adalimumab withdrawal. Arthritis Rheum 58:S580Google Scholar
  13. 13.
    Torrente V, Gratacos J, Juanola X, Sanmartí R, Suárez D, Moreno M, REMINEA group (2009) Infliximab withdrawal in patients with spondyloarthritis who presented criteria of clinical disease remission. An open study of clinical practise (REMINEA). Arthritis Rheum 60:S668CrossRefGoogle Scholar
  14. 14.
    Sidiropoulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K, Boumpas DT (2005) Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23:513–516PubMedGoogle Scholar
  15. 15.
    Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DGI (2006) Low-dose infliximab treatment for ankylosing spondylitis—clinically- and cost-effective. Rheumatology 45:1566–1569PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Victoria Navarro-Compán
    • 1
  • Virginia Moreira
    • 1
  • Rafael Ariza-Ariza
    • 1
    Email author
  • Blanca Hernández-Cruz
    • 1
  • Carmen Vargas-Lebrón
    • 1
  • Federico Navarro-Sarabia
    • 1
  1. 1.Rheumatology ServiceHospital Universitario Virgen MacarenaSevilleSpain

Personalised recommendations